Accelerating your therapeutic cancer vaccine, dendritic cell platform, and antiviral immunology programs — from preclinical models to clinical trials, for biotech companies and research teams.
Areas of Expertise
Over 30 years of research in academic scientific centers and biotech companies, from the fundamental mechanisms of anti-tumor immune responses to clinical trial design and next-generation therapy development — with a unique focus on translating preclinical insights into clinical impact, both in cancer and in antiviral immunology (chronic viral infections, vaccine responses, virus-induced malignancies).
Design and clinical development of therapeutic cancer vaccines, with a pioneering focus on allogeneic plasmacytoid dendritic cell (PDC)-based platforms. From preclinical proof-of-concept to phase I/II trials in solid tumors (NSCLC, melanoma) — bridging bench-to-bedside translation with rigorous immunological monitoring.
Deep expertise in dendritic cell (DC) biology, antigen presentation, and HLA-restricted CD8+ T-cell priming. Co-inventor of the PDC*line allogeneic platform (PDC*lung01, PDC*mel) enabling off-the-shelf, scalable cancer vaccines. Expert in immunological read-outs including flow cytometry-based CD8+ T-cell monitoring.
Combinatorial strategies associating therapeutic vaccines with PD-1/PD-L1 and CTLA-4 blockade. Interpretation of clinical data and predictive biomarkers of response in solid tumors and hematological malignancies.
About
Dr. Joël Plumas is an independent scientific consultant with over 30 years of experience at the interface of fundamental immunology, translational research, and clinical development. Trained as an immunologist (PhD, Université de Lille, 1992; HDR, Université Grenoble Alpes, 1998), he built his expertise at the Établissement Français du Sang (EFS) Rhône-Alpes, where he led the Cancer Immunobiology and Immunotherapy R&D laboratory for more than two decades.
A pioneer in plasmacytoid dendritic cell (PDC) biology, Joël co-founded PDC*line Pharma in 2014, where he served as Chief Scientific Officer, driving the development of the PDC*line allogeneic cancer vaccine platform from bench to clinical trials in NSCLC and melanoma. He was a Marie Curie Senior Fellow at University College London (Martin Pule Lab, 2010–2011), and received the Grand Prix Tremplin Entreprise Sciences de la Vie from INSERM Transfert in 2015.
Today, JPL's Consulting leverages this unique expertise — combined with AI-assisted scientific intelligence — to support biotech companies, academic teams, and investors with strategic consulting, rigorous literature synthesis, and preclinical-to-clinical translation.
Services
Supporting biotech and academic teams in designing and prioritizing immuno-oncology programs — with emphasis on preclinical-to-clinical translation, study design, and critical review of immunological protocols and data.
Bridging preclinical immunology data with clinical outcomes: analysis of CD8+ T-cell responses, immune biomarkers, tumor antigen-specific immunity, and translation of exploratory endpoints into clinically meaningful insights.
Critical assessment of the scientific potential of immuno-oncology projects for investors, partners, or scientific committees. Independent expert opinion on vaccine platforms, clinical data, and development strategies.
Structuring and editing of clinical study reports, investigational brochures, briefing documents for scientific advice, and scientific articles. From data to publication-ready deliverables aligned with journal and regulatory standards (IND, IMPD).
AI-assisted PubMed searches and thematic syntheses, ensuring relevance and accuracy of data. State-of-the-art reviews and competitive intelligence on therapeutic vaccines, cell therapies, and checkpoint inhibitors.
State-of-the-art presentations for clinical teams, training of R&D teams on fundamental concepts of tumor immunology and mechanisms of innovative immunotherapies.
Working Method
Every engagement begins with a deep dive into existing data, leading to actionable, scientifically grounded recommendations.
In-depth analysis of the scientific context, available data, and project objectives. Definition of deliverables and timeline.
Systematic exploration of PubMed with AI tools. Identification of recent publications and landmark studies, ensuring relevance and data accuracy.
Cross-referencing scientific data with the client's clinical or regulatory challenges. Identifying strengths, gaps, and opportunities.
Writing the report, manuscript, or recommendation. Iterative exchanges to refine conclusions and ensure alignment with objectives.
Selected Publications
A selection of key publications from 110+ peer-reviewed articles
Frontiers in Immunology · Front Immunol. 2026;17:1763434 · PMID 41859082
ESMO Open · ESMO Open. 2025;10(11):105844 · PMID 41101155
Hepatology Communications · Hepatol Commun. 2025;9(3):e0659 · PMID 40008881
International Journal of Molecular Sciences · Int J Mol Sci. 2023;24(3):1897 · PMID 36768214
Genes & Cancer · Genes Cancer. 2023;14:3–11 · PMID 36726965
Current Opinion in Oncology · Curr Opin Oncol. 2022;34(2):161–168 · PMID 34930882
Vaccines · Vaccines. 2021;9(2):141 · PMID 33578850
OncoImmunology · Oncoimmunology. 2020;9(1):1738812 · PMID 32313721
PNAS · Proc Natl Acad Sci USA. 2012;109(35):14122–7 · PMID 22879398
Journal of Clinical Investigation · J Clin Invest. 2008;118(10):3431–9 · PMID 18776940
Cytokine & Growth Factor Reviews · Cytokine Growth Factor Rev. 2008;19(1):79–92 · PMID 18155952
Blood · Blood. 2003;101(3):949–54 · PMID 12393572
Blood · Blood. 2001;97(10):3210–7 · PMID 11342451
Contact
Do you have an immuno-oncology project, need to develop your immunomonitoring assays, or want an expert eye on your data? Let's talk.
I will get back to you as soon as possible.
Thank you for your message. I will reply as soon as possible.